Medical Technologies
Sorafenib (Nexavar)
On February 14, 2012, KEI filed an affidavit in an India compulsory licensing case involving Bayer patents on cancer drug Sorafenib (Nexavar). The price for Nexavar in India is $47 per 200 milligram tablet. At a daily dose of 4 tablets, this comes to $5,637 per month, or more than $68 thousand per year. The per capita income in India was $1,330 in 2010.
Initial FDA approval
Date of FDA NDA application 21-923: Signed July 6, 2005. Received by FDA on July 8, 2005.
Date on FDA approval: December 20, 2005.
Comments on Incentivizing Humanitarian Technologies and Licensing Through the Intellectual Property System
Submitted by Anne Mira Guha on 2. March 2011 - 23:00On September 20, 2010, the PTO published "Request for Comments on Incentivizing Humanitarian Technologies and Licensing Through the Intellectual Property System" in the Federal Register (75 Fed. Reg. 57261, available here):
Prices for Abbott's Norvir (generic name Ritonavir) as a Standalone Product in 2010
Submitted by Anne Mira Guha on 10. August 2010 - 14:09KEI Research Note 2010:4
August 12, 2010
Anne Mira Guha
1. Introduction
Notes and data points for prices of orphan products
Submitted by James Love on 3. August 2010 - 13:50February 22, 2010., Matthew Herper, "The World's Most Expensive Drugs," Forbes.
Genzyme's web page on the cost of treatment.
Some data points on Fabrazyme prices.
US NGO’s Call For George Washington University to Cease Industry-Sponsored Intellectual Property Training in India
Submitted by Judit Rius on 9. June 2010 - 12:44On June 7, 2010 medicine access advocacy groups joined together in asking that George Washington University (GWU) put a stop to its industry-sponsored intellectual property (IP) summits and to take an academic, evidenced-based approach to conferences it conducts in India.
Indian NGOs confront GWU Law School efforts to push maximalist IPR norms in India
Submitted by Judit Rius on 4. March 2010 - 17:10The ties between Universities and businesses are often complex and blurred. Private companies or trade associations fund research and seminars, and have consulting relationships with faculty members, trying to shape public policy and judicial decisions on a wide range of issues. A particularly interesting industry/university connection concerns something called the "India Project," that is associated with the George Washington University (GWU) Law School.
March 28, 2001 Letter to US Secretary of Health and Human Services Tommy Thompson regarding access to NIH funded patents
March 28, 2001
Secretary Tommy Thompson
Department of Health and Human Services
200 Independence Avenue, SW
Washington, DC 20201
Dear Mr. Thompson:
September 1999 Letter to NIH, urging it provide the World Health Organization with access to U.S. government-funded medical inventions
Submitted by James Love on 17. September 2009 - 6:21Ralph Nader
P.O. Box 19312, Washington, DC 20036
James Love
Consumer Project on Technology
P.O. Box 19367, Washington, DC 20036
http://www.cptech.org
Robert Weissman
Essential Action
P.O. Box 19405, Washington, DC 20036
http://www.essentialaction.org/
September 3, 1999
Dr. Harold E. Varmus
Building 1, 126
National Institutes of Health
Bethesda, Maryland 20892
Congressional Hearings in 110th U.S. Congress, on pharmaceutical drugs (including trade issues)
U.S. Senate
Appropriations Committee
Subcommittee on Labor, Health and Human Services, and Education
April 18, 2007 Hearing on Global Health
Judiciary Committee
June 6, 2007 Patent Reform: The Future of American Innovation
Committee on Health, Education, Labor, and Pensions
UNITAID Patent Pool for Medicines
In 2007 Medécins sans Frontières (MSF, Doctors Without Borders) and Knowledge Ecology International (KEI) presented a proposal for UNITAID to host a medicines patent pool.
In July 2008 the UNITAID Board supported the principle of establishing a patent pool for medicines to provide patients in low and middle income countries with increased access to more appropriate and lower price medicines.
